- Report
- June 2022
- 11 Pages
Japan
- Report
- June 2022
- 17 Pages
Mexico
- Report
- May 2022
- 20 Pages
Paraguay
- Report
- May 2022
- 18 Pages
United Kingdom
- Report
- April 2022
- 22 Pages
Argentina
- Report
- April 2023
- 10 Pages
Latvia
- Report
- April 2023
- 15 Pages
Guyana
- Report
- April 2023
- 22 Pages
Australia
- Report
- March 2023
- 12 Pages
Serbia
- Report
- March 2023
- 15 Pages
Peru
- Report
- March 2023
- 18 Pages
Greece
- Report
- March 2023
- 15 Pages
Portugal
- Report
- August 2022
- 18 Pages
Uruguay
- Report
- July 2021
- 51 Pages
Denmark, Finland, ... Denmark, Finland, Iceland, Norway, Sweden
€2400EUR$2,697USD£2,122GBP
- Report
- July 2021
- 26 Pages
China
The Minor Cannabinoids market within the context of Analgesics is a rapidly growing sector of the pharmaceutical industry. It is focused on the development of novel cannabinoid-based drugs for the treatment of pain. These drugs are derived from the cannabis plant and are believed to have a range of therapeutic benefits, including the ability to reduce inflammation and provide relief from chronic pain. The Minor Cannabinoids market is driven by the increasing demand for alternative treatments for pain, as well as the growing acceptance of cannabis-based medicines.
The Minor Cannabinoids market is highly competitive, with a number of companies developing and marketing products. These companies are focused on the development of novel cannabinoid-based drugs, as well as the production of cannabis-based medicines. Some of the major players in the Minor Cannabinoids market include GW Pharmaceuticals, AbbVie, Insys Therapeutics, and Zynerba Pharmaceuticals. Show Less Read more